Literature DB >> 21502717

A long-term remission of renal amyloidosis with nephrotic syndrome after autologous peripheral blood stem-cell transplantation.

Kazuei Ogawa1, Kazuhiko Ikeda, Miki Furukawa, Kayo Harada-Shirado, Yumiko Mashimo, Hiroshi Takahashi, Hayato Matsumoto, Satoshi Kimura, Akiko Shichishima-Nakamura, Hiroshi Ohkawara, Yuko Hashimoto, Koichi Asahi, Hideyoshi Noji, Hitoshi Ohto, Yasuchika Takeishi.   

Abstract

Renal amyloidosis is typically characterized by nephrotic syndrome, often with massive proteinuria and refractory peripheral edema. We report the case of a patient with renal amyloidosis associated with nephrotic syndrome who maintained remission for 6 years after undergoing high-dose chemotherapy followed by autologous peripheral blood stem-cell transplantation (auto-PBSCT). The patient was a man aged in his 50s who had developed nephrotic syndrome. Bone marrow aspiration and kidney biopsy determined that the cause of the nephrotic syndrome was renal amyloidosis due to multiple myeloma, and the patient was admitted to our department in July 2003. After one course of chemotherapy, auto-PBSCT was performed in March 2004. Following transplantation, serum M-protein was no longer detectable from March 2005, and the patient achieved complete hematological remission. Subsequently, proteinuria decreased, serum albumin levels normalized, and nephrotic syndrome improved. As of 6 years after transplantation, in March 2010, the patient remained in remission, meaning that auto-PBSCT proved extremely effective as a treatment for renal amyloidosis in this case.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21502717     DOI: 10.5387/fms.56.151

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  1 in total

1.  Cure of relapsing nephrosis by an allogeneic marrow graft for chronic myelogenous leukemia.

Authors:  Keisuke Sugimoto; Naoki Sakata; Shinsuke Fujita; Tomoki Miyazawa; Hitomi Nishi; Tsukasa Takemura; Mitsuru Okada
Journal:  Pediatr Nephrol       Date:  2013-02-23       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.